HJHeather B. Jaspan

Heather B. Jaspan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Heather B. Jaspan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Alan J. Flisher

    Division of Child and Adolescent Psychiatry, University of Cape Town, South Africa

    1 shared publication
  • Alison E. MBChB Berrisford

    From the *School of Child and Adolescent Health, University of Cape Town; †Department of Pediatrics, Groote Schuur Hospital; and ‡School of Public Health and Family Medicine, University of Cape Town, South Africa

    1 shared publication
  • Andrew Boulle

    Centre for Integrated Data and Epidemiological Research, School of Public Health, University of Cape Town, South Africa

    1 shared publication
  • Ann E. Strode

    Faculty of Law, University of KwaZulu-Natal, South Africa

    1 shared publication
  • Catherine Mathews

    South African Medical Research Council, Cape Town, South Africa

    1 shared publication
  • Daniella Mark

    Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa

    1 shared publication

Latest Publications

  • Two-Year Outcomes of Children on Non-Nucleoside Reverse Transcriptase Inhibitor and Protease Inhibitor Regimens in a South African Pediatric Antiretroviral Program

    by Heather B. Jaspan, Alison E. MBChB Berrisford, Andrew M. MBChB Boulle

    Background: Few data exist on the efficacy of the limited regimens for children with HIV, which are available in sub-Saharan Africa. Methods: Retrospective cohort study to evaluate the clinical and laboratory outcomes of 391 children who received protease inhibitor (PI) or non-nucleoside reverse transcription inhibitor (nNRTI)-containing highly active antiretroviral regimens (HAART) from a Cape Town clinic. Endpoints included CD4% and count, viral loads, weight-for-age Z score (WAZ), survival, drug changes, and loss to follow-up over 24 months. A generalized estimating equation population-averaged model was used to identify associations with virological suppression, and a log-rank test explored associations with survival. Results: Overall, this cohort achieved a sustained doubling of median CD4% from baseline, steady increase of median WAZ, and survival of 91%, despite only 49% virologic suppression at 24 months. However, when analyzed according to regimen, PI-containing regimens had better virologic suppression at all time points. There were no differences in immunologic and growth endpoints between regimens or in survival. In a multivariate model predicting virologic suppression at any duration up to 24 months and adjusting for baseline CD4%, regimen, age, baseline WAZ, duration of HAART, and year of HAART initiation, nNRTI-based regimens (odds ratio [OR]: 0.38; 95% confidence interval [CI]: 0.19–0.77) and length of time on HAART were inversely associated with virologic suppression. Age (OR: 1.23 per year; 95% CI: 1.09–1.39) was positively associated with virologic suppression. Conclusions: The benefits of HAART are substantial in this setting, although PI regimens achieved greater virologic suppression than nNRTIs. Further exploration of regimens and dosing of antiretrovirals for children in these settings is needed.


  • Community perspectives on the ethical issues surrounding adolescent HIV vaccine trials in South Africa

    by Heather B. Jaspan, Nosiphiwo F. Soka, Ann E. Strode, Catherine Mathews, Daniella Mark, Alan J. Flisher, Robin Wood, Linda-Gail Bekker


  • Open Access

    The role of polyclonal intravenous immunoglobulin in treating HIV-infected children with severe bacterial infections: A retrospective cohort study

    by Lyen C Huang, Landon Myer, Heather B Jaspan

    Background: Mortality among HIV-infected children in developing countries remains high after serious bacterial infections despite the use of antibiotics. Intravenous immunoglobulin (IVIG) has been used as an adjuvant therapy to treat these infections, but little data exists regarding its efficacy, and previous studies have focused on IVIG as a prophylactic agent. We examined the impact of IVIG as an adjuvant therapy in reducing mortality and length of hospital stay in HIV-infected children with serious bacterial infections. Methods: This retrospective study focused on pediatric admissions at a large urban hospital between 2002 and 2006. Children between the ages of one month and nine years of age with laboratory confirmed HIV-status, serious bacterial infection, no prior exposure to IVIG, and a hospital length of stay of 5 days or more, were eligible for inclusion. Results: A total of 140 children (median age 1.2 years) met inclusion criteria; lower respiratory tract infection was diagnosed in 94 (67%) of the children, while 74 (53%) had bacterial sepsis. Fifty-four (39%) children were receiving antiretroviral therapy and 39 (28%) were receiving tuberculosis treatment. Overall 73 (52%) were treated with IVIG, with the majority (74%) of children receiving a single dose. Thirteen (9%) died during their hospital admission. In crude analysis IVIG was significantly associated with increased mortality was (Odds Ratio (OR): 5.8; 95% Confidence Interval (CI): 1.2–27.1) and this association was weakened by adjustment for other predictors of mortality (OR 4.3, 95% CI 0.7–27.9, p = 0.123). IVIG use was also associated with longer hospital stays. Conclusion: Administration of one to three doses of IVIG during the acute phase of illness does not appear to reduce mortality or the length of hospital stays in HIV-infected children with serious bacterial infections. However, the retrospective nature of this study makes confounding by indication difficult to control and further studies regarding the timing, dosing, and method of administration are required. Nonetheless the routine use of IVIG in resource-limited settings should be carefully considered given its high cost.


  • Preventing Neonatal HIV: A Review

    by Heather B. Jaspan, Robert F. Garry

    Mother-to-child transmission of human immunodeficiency virus type 1 has become rare in developed countries, with the use of highly active antiretroviral treatment, elective cesarean section, and avoidance of breastfeeding. In the developing world, however, these interventions are unfeasible, and costsaving methods for prevention of vertical transmission are vital. Prevention begins with voluntary counseling and testing, improved maternal education and access to prenatal care. Various antiretroviral drugs administered before, during, and for short periods after delivery have decreased vertical transmission. Where safe and compliant formula feeding is difficult, avoidance of mixed feeding may improve infant outcomes. However, post-natal transmission via breast milk remains a major challenge. As we continue to find cost-effective answers to protect infants worldwide, the search for a HIV-1 vaccine continues.